Allarity Therapeutics doses first patients in VA-funded Phase 2 trial of stenoparib + temozolomide for relapsed SCLC

Allarity Therapeutics, Inc.

First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).
Trial fully funded by U.S. Department of Veterans Affairs, enrolling at 11 VA medical centers nationwide.
Stenoparib is a dual PARP and WNT pathway inhibitor; prior PARP inhibitors limited by hematologic toxicity.
CEO cites fast enrollment and high unmet need; ~60-70% of SCLC patients present with extensive-stage disease.
Stenoparib crosses blood-brain barrier, relevant for SCLC brain metastases.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.